胰岛素抵抗与肺癌临床相关机制的研究进展

Progress in the Study of Mechanisms Clinically Relevant to Insulin Resistance and Lung Cancer

目前全球肺癌的发病率和死亡率均位居恶性肿瘤首位。肺癌的早期诊断、治疗和耐药仍是肺癌管理的难题。研究人员致力于寻找可靠的生物标志物作为肺癌的预测指标或治疗的有效靶点。胰岛素抵抗(insulin resistance,IR)是一种以胰岛素生物活性降低为特征的疾病,会导致胰岛素分泌增加。近年来,越来越多的研究发现IR与癌症的发生和进展之间存在联系,胰岛素/胰岛素生长因子信号通路在其中可能起到关键作用。本文重点阐述IR与肺癌之间的关系,探讨IR对肺癌发生、进展和耐药的影响及作用机制,以期指导新的预测工具和治疗策略的开发,为致力于降低肺癌发病率和死亡率的研究提供新思路。

At present,the incidence and mortality rates of lung cancer rank top among malignant tumors.The early diagnosis,treatment and drug resistance of lung cancer still remain as problems in the management of lung cancer.Researchers are dedicated to identifying reliable biomarkers as predictive indicators or effective therapeutic targets for lung cancer.Insulin resistance(IR),a disorder characterized by reduced biological activity of insulin,leads to increased insulin secretion.In recent years,more and more studies have revealed the association between IR and the occurrence and development of cancer,with the insulin/insulin-like growth factor signaling pathway possibly playing a crucial role.In this article,we will focus on the relationship between IR and lung cancer,explore the impact and mechanism of IR on the development,progression and drug resistance of lung cancer.It may guide the development of new predictive tools and therapeutic strategies,and provide new ideas for research dedicated to reducing the incidence and mortality of lung cancer.